Pfizer Covid-19 Vaccine Shows Over 90% Effectiveness in Clinical Trials
Pfizer and BioNTech report their coronavirus vaccine is more than 90% effective at preventing infection, far exceeding initial expert expectations. The breakthrough sparks a massive global market rally and offers renewed hope for ending the pandemic.
Pfizer and BioNTech announce that their coronavirus vaccine demonstrates more than 90% effectiveness in preventing Covid-19 among participants without prior infection. This early result from an independent analysis of the phase three clinical trial greatly exceeds the 50% to 75% efficacy threshold originally sought by scientists and health officials.
The clinical trial involves 43,538 participants, with the 90% efficacy rate calculated based on 94 confirmed Covid-19 infections split between those who receive the vaccine and those who get a placebo. Full protection requires a two-dose schedule, with immunity achieved 28 days after the initial vaccination, though the final efficacy percentage may shift as researchers continue to collect data.
Financial markets respond enthusiastically to the news, with the Dow Jones Industrial Average surging over 1,000 points and heavily impacted travel stocks like airlines and cruise lines seeing massive premarket jumps. Pfizer's CEO calls the development a historic milestone for public health and the global economy, providing a visible light at the end of the tunnel as the pandemic continues to disrupt daily life worldwide.